A

Amgen

Makes biotech medicines for serious illnesses

Encryption Agility Analyst

Full-TimeUpdated on 10/24/2026
No salary listed
Junior, Mid
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
CybersecuritySecurity Governance, Risk & Compliance

About the job

Requirements
  • A Master's degree and 1 to 3 years of experience in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field; or a Bachelor's degree and 3 to 5 years of experience in those areas; or a Diploma and 7 to 9 years of experience in those areas.
  • Working knowledge of information security and foundational enterprise cryptography, including Public Key Infrastructure (PKI), X.509 certificates, Transport Layer Security (TLS), cipher suites, Key Management Services (KMS), secrets management, key lifecycle, encryption at rest and in transit, cloud key services, and identity protocols.
  • Experience reviewing security tool outputs, maintaining inventory records, validating data quality, documenting findings, updating tickets, and supporting dashboards or operational reports.
  • Basic understanding of post-quantum cryptography, crypto agility, cryptographic discovery, Cryptographic Bill of Materials (CBOM) and Software Bill of Materials (SBOM) concepts, risk-based remediation, and Steal-Now-Decrypt-Later (SNDL) risk.
  • Ability to follow technical guidance, document evidence clearly, coordinate with service owners, and escalate complex cryptographic findings or exceptions appropriately.
  • Experience supporting CBOM/SBOM data management using CycloneDX 1.6 or later, Application Programming Interfaces (APIs), Comma-Separated Values (CSV), JavaScript Object Notation (JSON), spreadsheets, dashboards, data quality checks, and audit-ready reporting.
  • Experience supporting certificate lifecycle activities, certificate expiration tracking, certificate ownership updates, certificate rotation evidence, or PKI operational reporting.
  • Experience supporting cloud security, application security, Development and Operations (DevOps), Secure Software Development Life Cycle (SSDLC) governance, Continuous Integration/Continuous Delivery (CI/CD) quality gates, static analysis, dynamic analysis, composition analysis, or developer remediation tracking.
  • Experience in pharmaceutical, life sciences, regulated, validated, Good x Practice (GxP), Key Computerized Systems (KCS), manufacturing, Operational Technology (OT), or other change-controlled environments.
  • Experience supporting vendor or third-party risk activities, supplier questionnaires, roadmap tracking, evidence collection, or Software as a Service (SaaS) platform dependency analysis.
  • Foundational scripting or data handling experience with Python, PowerShell, Bash, Representational State Transfer Application Programming Interfaces (REST APIs), CSV files, JSON files, or lightweight reporting automation.
  • Interest and aptitude for improving human productivity through responsible automation and Artificial Intelligence (AI)-assisted workflows while maintaining accuracy, documentation quality, and appropriate escalation.
Responsibilities
  • Support Encryption Agility Service operations, including intake processing, work tracking, dashboard updates, meeting notes, service documentation, Standard Operating Procedures (SOPs) maintenance, reporting inputs, and service improvement actions.
  • Collect and validate cryptographic inventory data from source code, binaries, cloud key services, endpoints, file systems, network traffic, PKI and certificates, KMS and secrets, vendor attestations, SBOM inputs, and Subject Matter Expert (SME) interviews.
  • Maintain CBOM records using CycloneDX 1.6 or later as the target format, including required fields, source systems, asset ownership, quantum-vulnerability status, remediation status, data quality checks, reporting views, and ServiceNow asset correlation.
  • Review cryptographic scan outputs, certificate records and chains, cipher suite configurations, TLS and Secure Shell (SSH) settings, Open Authorization (OAuth), Security Assertion Markup Language (SAML), JSON Web Token (JWT) patterns, cloud key records, and key or secret storage evidence under L5 engineer or Principal Architect guidance.
  • Support data ingestion, tool integration, and evidence management across Amgen enterprise systems and cryptographic discovery platforms.
  • Assist Digital Identity Access Service (DIAS), PKI service owners, certificate management teams, and identity teams with certificate visibility, certificate ownership, expiration tracking, Certificate Lifecycle Manager (CLM) data needs, manual-to-automated deployment candidates, Certificate Authority (CA) roadmap inputs, and operational change window planning.
  • Assist cloud, infrastructure, and platform teams with KMS and secrets inventory, Hardware Security Module (HSM) evidence, key ownership records, key rotation status, key retirement tracking, storage standards, and reporting needed for centralized or federated key management controls.
  • Support Application Security, AI Security, Enterprise Architecture, DevOps, and engineering teams with approved cryptographic library adoption, CI/CD scan data, SSDLC requirements, scanning rules, secure code examples, and developer remediation playbooks.
  • Track remediation and risk prioritization data for business-critical applications, high-volume sensitive data flows, third-party dependencies, identity services, legacy platforms, KCS, validated GxP systems, and OT scope.
  • Support vendor and third-party governance activities with Procurement, Legal, Risk and Compliance, Third Party Risk Management (TPRM), and business owners by collecting technical questionnaire responses, CBOM requests, cryptographic evidence, roadmap updates, and supplier follow-up actions.
  • Maintain knowledge articles, implementation guides, training material, exception records, and escalation summaries while monitoring relevant updates from the National Institute of Standards and Technology (NIST), Internet Engineering Task Force (IETF), National Security Agency Commercial National Security Algorithm Suite 2.0 (NSA CNSA 2.0), International Organization for Standardization (ISO), Health Insurance Portability and Accountability Act (HIPAA), Health Information Trust Alliance (HITRUST), and broader industry cryptography guidance.
  • Support AI-enabled process orchestration by documenting manual Encryption Agility Service workflows, identifying repetitive evidence, inventory, reporting, and remediation tracking tasks, testing AI-assisted outputs, and maintaining human-in-the-loop review records for findings, exceptions, and decision-support material under L5 engineer or Principal Architect guidance.
Desired Qualifications
  • Experience with ServiceNow Configuration Management Database (CMDB)/Governance, Risk, and Compliance (GRC), Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, GitGuardian, Amazon Web Services (AWS) KMS, AWS Certificate Manager, AWS Secrets Manager, Microsoft PKI, Sectigo, HashiCorp Vault, HSMs, CLM platforms, or Security Information and Event Management (SIEM)/data lake tools.
  • Desired experience using AI-enabled tools, workflow automation, or AI agents to support security, governance, risk, compliance, reporting, data quality, or technology operations processes, including testing outputs, documenting human review points, and identifying opportunities to reduce repetitive manual work.
  • Desired familiarity with AI agent concepts, including agent roles, workflow orchestration, tool integration, human-in-the-loop review, output validation, audit trails, and escalation to engineers, architects, or service owners when AI-assisted outputs require technical or risk-based judgment.
  • Security+, Systems Security Certified Practitioner (SSCP), or equivalent foundational security certification.
  • Certified Information Systems Security Professional (CISSP) Associate, CISSP, Certified Information Security Manager (CISM), Certified Information Systems Auditor (CISA), or Certified in Risk and Information Systems Control (CRISC).
  • Certified Cloud Security Professional (CCSP), AWS Certified Security - Specialty, Microsoft Azure Security Engineer, or equivalent cloud security certification.
  • Information Technology Infrastructure Library (ITIL), Scaled Agile Framework (SAFe), product management, or equivalent delivery certification.
  • Relevant PKI, KMS, HSM, cryptographic discovery, certificate lifecycle management, cloud key management, or post-quantum cryptography training or certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.